ArticleBioengineering (Basel, Switzerland)2025
Voice-Based Early Diagnosis of Parkinson's Disease Using Spectrogram Features and AI Models.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Non-Invasive Voice-Based Early Detection of Parkinson's Disease via Spectral Feature Analysis and Machine Learning Techniques.Bioengineering (Basel, Switzerland) · 2026Article
- Demographic Confounding in Voice-Based Parkinson Disease Screening: Methodological Analysis of the Bridge2AI Voice Dataset.Journal of medical Internet research · 2026Article
- A Machine Learning Approach to Voice-Based Parkinson Disease Screening Using Multiview Spectrogram and Speech Recognition Features: Diagnostic Study.JMIR medical informatics · 2026Article
- A novel class-attention transformer-driven feature fusion technique-based speech disorder classification.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder that significantly affects motor functions, including speech production. Voice analysis offers a less invasive, faster and more cost-effective approach for diagnosing and monitoring PD over time. This research introduces an automated system to distinguish between PD and non-PD individuals based on speech signals using state-of-the-art signal processing and machine learning (ML) methods. A publicly available voice dataset (Dataset 1, 81 samples) containing speech recordings from PD patients and non-PD individuals was used for model training and evaluation. Additionally, a small supplementary dataset (Dataset 2, 15 samples) was created although excluded from experiment, to illustrate potential future extensions of this work. Features such as Mel-frequency cepstral coefficients (MFCCs), spectrograms, Mel spectrograms and waveform representations were extracted to capture key vocal impairments related to PD, including diminished vocal range, weak harmonics, elevated spectral entropy and impaired formant structures. These extracted features were used to train and evaluate several ML models, including support vector machine (SVM), XGBoost and logistic regression, as well as deep learning (DL)architectures such as deep neural networks (DNN), convolutional neural networks (CNN) combined with long short-term memory (LSTM), CNN + gated recurrent unit (GRU) and bidirectional LSTM (BiLSTM). Experimental results show that DL models, particularly BiLSTM, outperform traditional ML models, achieving 97% accuracy and an AUC of 0.95. The comprehensive feature extraction from both datasets enabled robust classification of PD and non-PD speech signals. These findings highlight the potential of integrating acoustic features with DL methods for early diagnosis and monitoring of Parkinson's Disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.